From Multi-Producer ViT to Multi-Centre Validation: 2026 of Caucinscope AI's non-diagnostic and non-moderated data base

The narrow necrosis of the choreography is one of the most difficult diagnostic challenges in clinical settings. The diagnostic sensitivity of standard ERCP samples is only 30-50%, and repeated negative active examinations may lead to delayed diagnosis of malignant pathologies. The choreography lens (POCS/SpyScope) can directly observe the inner walls of the choreography, but under the lens judgement is still highly empirical.

In 2025, the ViT-based Caucophagus-Scientific system, which has achieved cross-managerial diagnostic consistency between Olympus and Boston Scientific equipment, has superior non-diagnostic performance to CNN. Multi-centre validation shows that AI identifies malignant disease as continuing to be better than standard ERCP sampling methods. Longwaytech supports this breakthrough with a 1 million case of Caucoca-Sciento-Speciscope video set.

Unlike the first one developed mainly on single-manufacturing equipment, the first one requires to handle images of different manufacturers such as Olympus CHF-B260/B290 and Boston Scientific SpyScope DS/DS II. Trans-producer transmantivity is key to clinical outreach - different equipment configurations in different hospitals, and if AI can only work on specific plant equipment, it will severely limit its scope of application.

The development of the Cinnaline mirrors AI achieved a structural leap from CNN to ViT in 2025.

At the technical level, the ViT architecture POCS AI, published in 2025 by the Digital Endoscopy, has achieved cross-manufacturing convergence between Olympus and Boston Scientific. The core of this breakthrough lies in the ViT’s “global focus” mechanism – unlike CNN’s local sense of the region, which can model the relationships between any region in the image, a global perspective that allows models to learn generic features that are not related to the equipment.

At the validation level, the 2025 multi-centre validation study showed that AI continued to outperform standard ERCP sampling methods in identifying malignant pathologies. The system overview and thallium analysis showed that AAAAAAAAAAACs had a diagnostic value for uncertainty and a narrow choreography.

At the general level, the 2025 overview noted that AI had been used in EUS for cystic disease detection and pancreatic edema recognition, but that the application of choreal and cholesterol cancer AI was still at an early stage.

In terms of market size, the global ERCP and Cyclops market is expected to be over $1.2 billion in 2026, and AI’s supporting diagnosis is an emerging growth point. China’s incidence of cholesterol cancer is high in some parts of the country, with a unique application value for cholesterol mirrors.

The core breakthrough of the Caucinscope AI in 2025 was concentrated on three areas.

The first is the cross-producerization of ViT. The traditional CNN model is very different in terms of the different manufacturers’ equipment, because CNN’s collages tend to learn specific texture features of the equipment. ViT’s global attention mechanism can model more abstract visual features, independent of the specific texture differences of the equipment. This breakthrough allows AI to operate on different hospital equipment without having to train individual models for each device.

The second is multi-centre validation. The results of the multi-centre validation show that AI identifies malignant pathologies as persistent superior to standard ERCP sampling. This results are significant - standard ERCP sampling has a sensitivity rate of only 30-50%, and AI support can significantly increase the detection rate of malignant pathogenesis and reduce delays in diagnosis.

The third is the system overview and the Meta analysis. The systematic overview and the spectroscopy of Houston Methodist show that ACVD is diagnosticly valuable for uncertainty and the narrowness of the virulent choreography, providing evidence-based medical support for effectiveness in this area.

The 1 million cases of cholesterol lenses in Longway Technology provide a key support for these frontier studies. The data sets support multi-manufacturing equipment data such as Olympus and Boston Scientific, which indicate consistency across equipment, along with a narrow necrosis, quartz/tumour/inflammation marker and proof of pathology.

The Longhui technology Cough Pancreatic Spectroscope video set, with a scale of 1 million cases, systematically covers the entire process of screening the pancreatic lens.

In terms of data collection, all images are from the cooperative digestive internal and liver cholesterol surgery at the San Ace Hospital. Full records of the whole ERCP cholesterol examination process, with a galley choreary tube/hepatococal tube/ pancreas/bourbon.

In the case of labelling systems, each data includes structured fields such as choreography/longing of the choreography, surface form, angiogenesis, stone/tumour/inflammation, biopsy, pathology, etc. The label is consistent across the equipment to ensure that the standard for labelling of different plant equipment is uniform.

In terms of data distribution, the pathological pathologies are identified as the main subject; the benign narrowness, inflammation and uncertain cases are retained. This stratification allows models to learn from continuous patterns of change from benign to malignant.

In terms of quality control, the three-layer process of control of the first bid for a digestive physician + the deputy director and above expert review + consistency assessment is used. Particular attention is paid to the consistency of cross-equipment labelling and the accuracy of the narrow choreography of the choreography.

Data sets prioritize formal ERP reports, choreology of choreography, ERCP cytology, EUS and follow-up data to support joint multi-modular learning.

The future of the pancreas mirror AI will go in three directions.

The first is a paradigm extension across manufacturers. The success of ViT cross-producerization provides a paradigm for other endoscope fields. If ViT can extend between different incline mirrors, the same approach may apply to other endoscope areas, such as gastrointestinal and bronchoscopes.

The second is from Image Classification to Real-Time Navigation. The navigation of cholesterol lenses in the ERCP is more challenging than gastrointestinal mirrors -- the choreography is highly variable and narrow. AI can indicate the narrow range of sections in real time, direct the prosecution to improve the efficiency of the examination.

The third is "aided diagnosis" to "the therapeutic guidance." Not only can AI identify badness, but it can also guide treatment decisions -- is it desirable to expand? Is it appropriate to include a badness narrowness? By combining image characteristics and clinical information, AI can provide data to support treatment decisions.

In terms of industry competition, the core competitiveness of the cholesterol lens data set, with multi-manufacturing equipment data, multi-centre distribution, and a proven pathology link, is one million examples of Longhuitech.

The leap of pancreas mirror AI from CNN to ViT across the firm has revealed the critical position of cross-producer in the clinical promotion of insulation. A true clinical spread can only be achieved if AI works steadily on different manufacturers’ equipment.

Long Salang Langhui Information Technology Ltd., with a million cases of cinnamon mirror video data set as its anchor, is becoming an important data provider in the pancreatic mirror AI field. At a critical time when ViT cross-producer breakthroughs and multiple centres of validation, Long Hui Technologies will continue to drive the clinical downfall of bold diagnosis with high-quality data.

The combination of different types of equipment, high imaging quality, complex anatomy structures, and a wide variety of disease types makes cross-protocol universalization of the AMA a central challenge. The model based on the cross-producer ViT structure made breakthrough progress in this direction in 2026, achieving stability in a variety of equipment through self-adaptation of the single model through self-training in imaging of different manufacturers’ equipment.

In the course of the examination, Cycloplasm AI can identify the narrow-mindedness, stench-like disease and mucous membranes in real time, guide the target to work and improve the diagnosis success rate. The data set of Long Cycter links pathology confirmation, ERCP parameters and follow-up data, supporting the full process AI enabling the detection of disease and diagnosis aids to treatment planning. The company is working with experts in the field of intra-corrigid and liver-coward surgery to advance the multi-centre clinical validation of Cycinosis Ai, which is dedicated to addressing the clinical pains of early diagnosis of cycotic diseases.